Country: Canada
Language: English
Source: Health Canada
KETOROLAC TROMETHAMINE
AA PHARMA INC
M01AB15
KETOROLAC
10MG
TABLET
KETOROLAC TROMETHAMINE 10MG
ORAL
100
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0121995001; AHFS:
APPROVED
2015-11-10
_ _ _TORADOL_ _® _ _(Ketorolac Tromethamine Tablets) _ _Page 1 of 56_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TORADOL ® Ketorolac Tromethamine Tablets Tablets, 10 mg, For Oral Use House Standard Non-Steroidal Anti-Inflammatory Drug (NSAID) AA Pharma Inc. 1165 Creditstone Road, Unit#1 Vaughan, Ontario L4K 4N7 Date of Initial Authorization: JUN 16, 2017 Date of Revision: APRIL 4, 2023 Submission Control Number: 267475 TORADOL is a registered trademark used under license by AA Pharma Inc. _ _ _TORADOL_ _® _ _(Ketorolac Tromethamine Tablets) _ _Page 2 of 56_ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 04/2023 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 04/2023 7 WARNINGS AND PRECAUTIONS, Skin 04/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant women 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 6 4 DOSAGE AND ADMINISTRATION .................................................................................. 7 4.1 Dosing Con Read the complete document